Genomics & Biotech: Precision Medicine Is Reshaping Drug Development

Thermo Fisher Scientific, one of the largest life-science infrastructure companies on the planet, sits at the foundation of the genomics-biotech theme. Without its reagents, instruments, and cold-chain logistics, most of what the other 95 companies in this graph do simply doesn't happen. That infrastructure layer — anchored by TMO and Danaher — is the least glamorous part of the theme and historically one of the most durable. Both companies supply the picks-and-shovels regardless of which clinical bets pay off.

Above that base layer, the theme is defined by a generational shift in how drugs are discovered and built. Gene-level precision is now the design spec, not the aspiration. Beam Therapeutics exemplifies this: the company uses base editing to make single-letter corrections to DNA without cutting the double helix, reducing the off-target risk that plagued first-generation CRISPR. Meanwhile, companies like Agilent Technologies provide the analytical instruments that validate every edit made anywhere in the pipeline.

The Commercial Engine Is Already Running

Vertex Pharmaceuticals proved that genomic medicine can scale commercially. Its CRISPR-based sickle cell therapy, developed with a partner, became the first approved gene-editing treatment. That approval resets the expectation for the entire theme — regulators have a framework, payers are negotiating, and the clinical blueprint exists. Bristol Myers Squibb and Amgen bring the commercial infrastructure — global sales forces, manufacturing scale, and balance sheets — that smaller genomic companies need to reach patients at volume.

IQVIA Holdings plays a different but critical role. As the dominant data and clinical-trial execution platform, it processes the real-world evidence that regulators increasingly require for genomic drugs. More genomic programs in the pipeline means more complex trials, which means more demand for exactly what IQV sells.

The Risk Stack Runs from Science to Balance Sheet

The further you move from the infrastructure layer, the more binary the outcomes. Celcuity is building precision diagnostics to match patients to PI3K-targeted therapies — a real unmet need, but one that requires companion diagnostic approval alongside the drug. CervoMed is targeting neuroinflammation in dementia, a space that has destroyed capital for two decades. Clinical-stage companies in this theme live and die by readout dates, and most carry limited cash runways.

Radiopharmaceuticals add another dimension. Radiopharm Theranostics targets tumors with isotope-labeled molecules that both image and destroy cancer cells — a modality that received a major commercial endorsement when Eli Lilly acquired a radiopharmaceuticals leader for a substantial sum. That transaction confirmed buyer appetite for the modality even before full commercial proof.

The theme's breadth is the point. Platform companies like Fortrea Holdings, spun out of Labcorp to focus on clinical contract research, benefit from any increase in trial activity across the whole pipeline. When sequencing gets cheaper and editing gets cleaner, more programs enter the clinic — and the services layer absorbs that volume directly. Investors who want exposure to the genomic wave without picking single clinical-stage binary bets have a real pathway through the infrastructure and services names.

The 96-company graph reflects how widely the genomic toolkit has spread. Explore the full company set and coverage in the ETF library to see where diversified exposure is available.